FFAR2 signaling modulates gut homeostasis by regulating SCFA-mediated responses. Studies using the FFAR2 Antibody have demonstrated its expression in intestinal enteroendocrine cells (K and L cells), which secrete hormones like GLP-1 and PYY to control glucose metabolism and appetite . In Apc mutant mice (a model for colorectal cancer), FFAR2 expression correlates with polyp formation, suggesting its role in intestinal carcinogenesis .
The antibody has been used to study FFAR2's anti-inflammatory effects. Activation of FFAR2 suppresses pro-inflammatory cytokine production in neutrophils and macrophages, while promoting chemotaxis and antimicrobial peptide release . In viral infections (e.g., respiratory syncytial virus), FFAR2 agonists reduce pulmonary inflammation, as demonstrated by antibody-based knockdown experiments .
Immunohistochemistry with the FFAR2 Antibody reveals its expression in astrocytes of mouse and rat hippocampi, linking it to neuroinflammation . In cancer research, FFAR2 is detected in various tumor cell lines (e.g., colon, breast, liver cancers), where its signaling may influence tumor growth and metastasis .
Future Directions
Emerging research focuses on therapeutically targeting FFAR2 to address metabolic disorders, infections, and cancer. The FFAR2 Antibody is a critical tool for validating receptor expression in preclinical models and exploring its downstream signaling pathways. Ongoing studies aim to elucidate FFAR2's dual Gαq/Gαi signaling mechanisms and its interaction with the gut microbiome .